Data Year:

For its 2025 fiscal year, LILLY (ELI) & CO, listed the following executives on its annual proxy statement to the SEC

Equity
Cash Compensation
Other
Fiscal Year Ended in 2025
Name And Title Total Compensation Pay Rank By Title In Biotechnology industry
David A. Ricks
Chair, President, and Chief Executive Officer
Total Compensation $32,246,701 View details Pay Rank By Title In Biotechnology industry #5 View more
Daniel M. Skovronsky M.D., Ph.D.
Executive Vice President, Chief Scientific and Product Officer and President, Lilly Research Labs
Total Compensation $16,898,731 View details Pay Rank By Title In Biotechnology industry #1 View more
Anat Hakim
Executive Vice President, General Counsel and Secretary
Total Compensation $9,342,570 View details Pay Rank By Title In Biotechnology industry #2 View more
Jake Van Naarden
Executive Vice President and President, Lilly Oncology and Head of Corporate Business Development
Total Compensation $7,498,730 View details Pay Rank By Title In Biotechnology industry #19 View more
Lucas Montarce
Executive Vice President and Chief Financial Officer
Total Compensation $8,240,000 View details Pay Rank By Title In Biotechnology industry #14 View more

The charts on this page feature a breakdown of the total annual pay for the top executives at LILLY (ELI) & CO as reported in their proxy statements.

Total Cash Compensation information is comprised of yearly Base Pay and Bonuses. LILLY (ELI) & CO income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. LILLY (ELI) & CO annual reports of executive compensation and pay are most commonly found in the Def 14a documents.

Total Equity aggregates grant date fair value of stock and option awards and long term incentives granted during the fiscal year.

Other Compensation covers all compensation-like awards that don't fit in any of these other standard categories. Numbers reported do not include change in pension value and non-qualified deferred compensation earnings.

Name And Title Total Cash Equity Other Total Compensation
David A. Ricks
Chair, President, and Chief Executive Officer
Total Cash $8,185,500 Equity $23,325,000 Other $736,201 $32,246,701
Daniel M. Skovronsky M.D., Ph.D.
Executive Vice President, Chief Scientific and Product Officer and President, Lilly Research Labs
Total Cash $4,739,424 Equity $12,000,000 Other $159,307 $16,898,731
Anat Hakim
Executive Vice President, General Counsel and Secretary
Total Cash $3,180,000 Equity $6,000,000 Other $162,570 $9,342,570
Jake Van Naarden
Executive Vice President and President, Lilly Oncology and Head of Corporate Business Development
Total Cash $2,926,211 Equity $4,500,000 Other $72,519 $7,498,730
Lucas Montarce
Executive Vice President and Chief Financial Officer
Total Cash $3,180,000 Equity $5,000,000 Other $60,000 $8,240,000
For its 2025 fiscal year, LILLY (ELI) & CO, listed the following CEO pay ratio data on its annual proxy statement to the SEC.
CEO Name CEO Pay Median Employee Pay CEO Pay Ratio
David A. Ricks CEO Pay $36,698,337 Median Employee Pay $125,100 CEO Pay Ratio 293:1
For its 2025 fiscal year, LILLY (ELI) & CO, listed the following board members on its annual proxy statement to the SEC.
Name Total COMPENSATION
Carolyn R. Bertozzi Total Cash $7,677
Gabrielle Sulzberger Total Cash $365,500
J. Erik Fyrwald Total Cash $343,803
Jamere Jackson Total Cash $368,000
Jonathan Moeller Total Cash $357,333
Juan R. Luciano Total Cash $398,000
Katherine Baicker, Ph.D. Total Cash $361,000
Kimberly H. Johnson Total Cash $336,000
Mary Lynne Hedley Total Cash $339,000
Ralph Alvarez Total Cash $361,000
William G. Kaelin, Jr., M.D. Total Cash $392,000
Browse Board of Directors By First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Executives by First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Companies by Company Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

This report is not for commercial use. Thorough reviews have been conducted to assure this data accurately reflects disclosures. However for a complete and definitive understanding of the pay practices of any company, users should refer directly to the actual, complete proxy statement.

Use of Data / Disclaimer

The information shown here is a reporting of information included in the company's proxy statement. The proxy statement includes footnotes and explanations of this information plus other information that is pertinent in assessing the overall value and appropriateness of the compensation information. For those interested in conducting a detailed compensation analysis, we recommend that you review the entire proxy statement. You may retrieve the full proxy statement by going to the Securities and Exchange Commission (SEC) website at www.sec.gov and entering the company's name and then looking in the first column for an entry of "Form DEF 14A" (or any similar code). You may also find the annual proxy statement by going directly to the company's website.

What is a proxy statement?

A proxy statement (or "proxy") is a form that every publicly traded U.S. company is required to file with the U.S. Securities & Exchange Commission (SEC) within 120 days after the end of its fiscal year. The proxy must be sent to every shareholder in advance of the company's annual shareholders meeting. All proxy statements are public filings made available to the general public by the SEC.

The proxy statement's main purpose is to alert shareholders to the annual meeting and provide them information about the issues that will be voted on during the annual meeting, including decisions such as electing directors, ratifying the selection of auditors, and other shareholder-related decisions, including shareholder-initiated initiatives. Also, proxies must disclose specific detailed information regarding the pay practices for certain executives.